Ingen klinisk signifikant reduktion i glimepirid AUC og Cmax blev observeret efter gentagne doser af rosiglitazon i 8 dage hos raske voksne personer.
No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of rosiglitazone for eight days in healthy adult subjects.